开发一种CA125-间皮素细胞黏附测定法作为生物制剂发现的筛选工具。
Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.
作者信息
Scholler Nathalie, Garvik Barbara, Hayden-Ledbetter Martha, Kline Toni, Urban Nicole
机构信息
Molecular Diagnostics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109-1024, USA.
出版信息
Cancer Lett. 2007 Mar 8;247(1):130-6. doi: 10.1016/j.canlet.2006.03.029. Epub 2006 May 4.
Abstract
Preventing peritoneal implantation of ovarian carcinoma cells could prolong patient remission and survival. CA125 is expressed on most ovarian cancer cells and was reported to be a ligand of mesothelin, a peritoneal protein. We developed a cell adhesion assay with CA125-expresser ovarian cancer cells and human mesothelin-transfected cells and we confirmed that CA125 and mesothelin mediate cell attachment. We also showed that this assay supplies a high-throughput screening system for reagents able to block CA125/mesothelin-dependent cell attachment with a sensitive quantitative readout. We finally demonstrated that a mesothelin chimeric protein and anti-CA125 antibodies block CA125/mesothelin-dependent cell attachment.
摘要
预防卵巢癌细胞的腹膜种植可延长患者的缓解期和生存期。大多数卵巢癌细胞都表达CA125，据报道它是一种腹膜蛋白间皮素的配体。我们利用表达CA125的卵巢癌细胞和转染了人源间皮素的细胞开发了一种细胞黏附试验，并证实CA125和间皮素介导细胞黏附。我们还表明，该试验为能够阻断CA125/间皮素依赖性细胞黏附的试剂提供了一个高通量筛选系统，并具有灵敏的定量读数。我们最终证明，一种间皮素嵌合蛋白和抗CA125抗体可阻断CA125/间皮素依赖性细胞黏附。
相似文献
1
Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.开发一种CA125-间皮素细胞黏附测定法作为生物制剂发现的筛选工具。
Cancer Lett. 2007 Mar 8;247(1):130-6. doi: 10.1016/j.canlet.2006.03.029. Epub 2006 May 4.
2
Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment.可预防CA125/间皮素依赖性细胞黏附的抗间皮素双特异性抗体的研发及体外验证
Cancer Lett. 2007 Oct 8;255(2):263-74. doi: 10.1016/j.canlet.2007.04.012. Epub 2007 Jun 7.
3
A binding domain on mesothelin for CA125/MUC16.间皮素上CA125/MUC16的结合域。
J Biol Chem. 2009 Feb 6;284(6):3739-49. doi: 10.1074/jbc.M806776200. Epub 2008 Dec 15.
4
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.卵巢癌抗原CA125/MUC16与间皮素的结合介导细胞黏附。
J Biol Chem. 2004 Mar 5;279(10):9190-8. doi: 10.1074/jbc.M312372200. Epub 2003 Dec 15.
5
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.间皮素与MUC16的结合是一种高亲和力、N-聚糖依赖性相互作用，它促进卵巢肿瘤的腹膜转移。
Mol Cancer. 2006 Oct 26;5(1):50. doi: 10.1186/1476-4598-5-50.
6
Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway.游离 CA125 通过与间皮素结合减少 DKK1 的表达并激活 SGK3/FOXO3 通路从而促进卵巢癌细胞迁移和肿瘤转移。
Int J Biol Sci. 2021 Jan 14;17(2):574-588. doi: 10.7150/ijbs.52097. eCollection 2021.
7
Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.评估上皮性卵巢癌患者血浆、腹腔积液和肿瘤组织中间皮素水平的临床病理相关性。
Tumour Biol. 2018 Oct;40(10):1010428318804937. doi: 10.1177/1010428318804937.
8
Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma.间皮素和 CA125 的共表达与子宫内膜浆液性癌和包括浆液性癌在内的混合癌的不良预后相关。
Pathol Oncol Res. 2020 Oct;26(4):2299-2306. doi: 10.1007/s12253-020-00823-1. Epub 2020 May 28.
9
Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.卵巢癌的腹膜播散：MUC16-间皮素相互作用的作用及其对治疗的影响。
Expert Rev Anticancer Ther. 2018 Feb;18(2):177-186. doi: 10.1080/14737140.2018.1418326. Epub 2017 Dec 21.
10
Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.评估卵巢癌缓解标志物 HE4、MMP7 和间皮素，并与既定标志物 CA125 进行比较。
Gynecol Oncol. 2012 Apr;125(1):65-9. doi: 10.1016/j.ygyno.2011.11.050. Epub 2011 Dec 7.
引用本文的文献
1
Peritoneal cavity-derived small extracellular vesicles from aged tumor-naïve hosts promote ovarian cancer adhesion and invasion.来自老龄未患肿瘤宿主的腹腔源性小细胞外囊泡促进卵巢癌的黏附和侵袭。
Cell Commun Signal. 2025 Jul 1;23(1):308. doi: 10.1186/s12964-025-02273-1.
2
Modern Emerging Biosensing Methodologies for the Early Diagnosis and Screening of Ovarian Cancer.用于卵巢癌早期诊断和筛查的现代新兴生物传感方法
Biosensors (Basel). 2025 Mar 21;15(4):203. doi: 10.3390/bios15040203.
3
Regulation of ovarian cancer by protein post-translational modifications.蛋白质翻译后修饰对卵巢癌的调控
Front Oncol. 2024 Nov 29;14:1437953. doi: 10.3389/fonc.2024.1437953. eCollection 2024.
4
Evolving landscape of detection and targeting miRNA/epigenetics for therapeutic strategies in ovarian cancer.卵巢癌治疗策略中用于检测和靶向微小RNA/表观遗传学的不断演变的格局。
Cancer Lett. 2024 Nov 29;611:217357. doi: 10.1016/j.canlet.2024.217357.
5
Metastasis of cervical cancer indicated by elevation of serum CA125 produced by mediastinal lymph nodes: a case report.纵隔淋巴结产生的血清 CA125 升高提示宫颈癌转移：一例报告。
J Med Case Rep. 2024 Feb 25;18(1):112. doi: 10.1186/s13256-024-04417-2.
6
Ligand-based adoptive T cell targeting CA125 in ovarian cancer.基于配体的过继性 T 细胞靶向卵巢癌 CA125。
J Transl Med. 2023 Sep 5;21(1):596. doi: 10.1186/s12967-023-04271-8.
7
Challenges of Anti-Mesothelin CAR-T-Cell Therapy.抗间皮素嵌合抗原受体T细胞疗法面临的挑战
Cancers (Basel). 2023 Feb 21;15(5):1357. doi: 10.3390/cancers15051357.
8
Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer.评估血清 CA125-Tn 糖型在高级别浆液性卵巢癌腹膜播散和手术完整性中的作用。
J Ovarian Res. 2022 Dec 23;15(1):134. doi: 10.1186/s13048-022-01066-1.
9
MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer.MSLN作为卵巢癌的一种预后生物标志物与免疫浸润和化疗耐药相关。
Front Oncol. 2022 May 25;12:830570. doi: 10.3389/fonc.2022.830570. eCollection 2022.
10
The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets.间皮素表达在浆液性卵巢癌中的作用：对诊断、预后及治疗靶点的影响
Cancers (Basel). 2022 May 3;14(9):2283. doi: 10.3390/cancers14092283.
本文引用的文献
1
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.血清间皮素的检测与定量，间皮素是一种用于间皮瘤和卵巢癌患者的肿瘤标志物。
Clin Cancer Res. 2006 Jan 15;12(2):447-53. doi: 10.1158/1078-0432.CCR-05-1477.
2
Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125.由卵巢肿瘤标志物CA125介导的自然杀伤细胞反应的强效抑制。
Gynecol Oncol. 2005 Dec;99(3):704-13. doi: 10.1016/j.ygyno.2005.07.030. Epub 2005 Aug 29.
3
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.间皮瘤和卵巢癌患者对间皮素的体液免疫反应。
Clin Cancer Res. 2005 May 15;11(10):3814-20. doi: 10.1158/1078-0432.CCR-04-2304.
4
Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity.乳腺癌疫苗：通过激发宿主免疫力实现癌症治疗的最大化。
Endocr Relat Cancer. 2005 Mar;12(1):1-17. doi: 10.1677/erc.1.00671.
5
Treatment advances in ovarian cancer.卵巢癌的治疗进展
Cancer Nurs. 2003 Dec;26(6 Suppl):16S-20S. doi: 10.1097/00002820-200312001-00005.
6
Recent advances in the management of women with ovarian cancer.卵巢癌女性患者管理的最新进展
Minerva Ginecol. 2004 Feb;56(1):81-9.
7
Progress and challenges in screening for early detection of ovarian cancer.卵巢癌早期检测筛查的进展与挑战
Mol Cell Proteomics. 2004 Apr;3(4):355-66. doi: 10.1074/mcp.R400006-MCP200. Epub 2004 Feb 5.
8
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.卵巢癌抗原CA125/MUC16与间皮素的结合介导细胞黏附。
J Biol Chem. 2004 Mar 5;279(10):9190-8. doi: 10.1074/jbc.M312372200. Epub 2003 Dec 15.
9
Mesothelin-family proteins and diagnosis of mesothelioma.间皮素家族蛋白与间皮瘤的诊断
Lancet. 2003 Nov 15;362(9396):1612-6. doi: 10.1016/S0140-6736(03)14794-0.
10
Sensitization of breast cancer cells to radiation by trastuzumab.曲妥珠单抗使乳腺癌细胞对放疗敏感。
Mol Cancer Ther. 2003 Nov;2(11):1113-20.
Zotero 插件